Drugs / RAY1225
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07460284 | Mar → Oct 2026 expected | — | Guangdong Raynovent Biotech Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07362030 | Apr → Dec 2025 overdue | obesity disorder | Guangdong Raynovent Biotech Co., Ltd | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06613763 | Sep 2024 → Jan 2025 | impaired renal function disease | Guangdong Raynovent Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06577415 | Aug 2024 → Oct 2025 overdue | — | Guangdong Raynovent Biotech Co., Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT06577428 | Jul → Sep 2024 | — | Guangdong Raynovent Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT05835752 | May 2023 → Mar 2024 | obesity disorder | Guangdong Raynovent Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06254274 | Feb 2024 → Dec 2025 overdue | type 2 diabetes mellitus | Guangdong Raynovent Biotech Co., Ltd | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06254261 | Feb 2024 → Dec 2025 overdue | obesity disorder | Guangdong Raynovent Biotech Co., Ltd | Recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07139535 | Aug 2025 → Dec 2026 expected | type 2 diabetes mellitus | Guangdong Raynovent Biotech Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07139548 | Aug 2025 → Dec 2026 expected | type 2 diabetes mellitus | Guangdong Raynovent Biotech Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06893016 | Jun 2025 → Jun 2026 overdue | obesity disorder | Guangdong Raynovent Biotech Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RAY1225 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06577415 ↗ |
| Route | Subcutaneous | “Escalating doses of RAY1225 administered subcutaneously (SC) once in healthy participants.” NCT05835752 ↗ |